• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硬皮病合并法布里病患者的限制性心肌病:基于病例的综述。

Restrictive cardiomyopathy in a patient with systemic sclerosis and Fabry disease: a case-based review.

机构信息

Internal Medicine, Universidad Libre, Cali, Colombia.

Arthritis and Rheumatology Clinic, Centro Médico Imbanaco, Cali, Colombia.

出版信息

Rheumatol Int. 2020 Mar;40(3):489-497. doi: 10.1007/s00296-019-04453-y. Epub 2019 Oct 10.

DOI:10.1007/s00296-019-04453-y
PMID:31599343
Abstract

Systemic sclerosis (SSc) is a rare immune-mediated vasculopathy characterized by fibrosis of the skin and internal organs. Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the GLA gene producing α-galactosidase-A enzyme (α-Gal A) deficiency. Being a systemic disease, cardiac involvement in FD has a high mortality rate due to heart failure and arrhythmia. The coexistence of these two entities has not been reported previously. We describe the case of a female patient with limited SSc (lcSSc), a diagnosis based on the presence of sclerodactyly, Raynaud phenomenon, microvascular involvement, and positive anti-centromere antibodies. On follow-up, she developed chest pain, a second-degree A-V block, and restrictive cardiomyopathy (without cardiovascular risk factors). Although heart involvement is common in these two entities, the abnormal thickening of lateral and inferior wall, the infiltration pattern and the conduction system disorders presented herein are more characteristic in a heterozygous female with a cardiac variant of FD. The diagnosis of FD was confirmed with high globotriaosylsphingosine (Lyso-Gb3) levels and identification of GLA gene mutation. The patient was treated with enzymatic replacement (agalsidase alpha) following mild improvement in ventricular mass at 6th month, without clinical deterioration. The related literature on SSc associated with FD is also reviewed.

摘要

系统性硬化症(SSc)是一种罕见的免疫介导性血管病变,其特征为皮肤和内脏器官纤维化。法布里病(FD)是一种 X 连锁溶酶体贮积病,由 GLA 基因突变导致α-半乳糖苷酶-A 酶(α-Gal A)缺乏引起。由于 FD 是一种全身性疾病,心脏受累的死亡率很高,原因是心力衰竭和心律失常。这两种疾病同时存在以前没有报道过。我们描述了一例局限性系统性硬化症(lcSSc)女性患者的病例,该患者的诊断基于硬皮病、雷诺现象、微血管受累和阳性抗着丝点抗体的存在。随访时,她出现胸痛、二度房室传导阻滞和限制性心肌病(无心血管危险因素)。尽管这两种疾病都常见心脏受累,但此处出现的外侧和下壁异常增厚、浸润模式和传导系统障碍在 FD 的心脏变异型杂合子女性中更具特征性。通过检测高 globotriaosylsphingosine(Lyso-Gb3)水平和鉴定 GLA 基因突变,确诊 FD。该患者接受了酶替代治疗(agalsidase alpha),6 个月时心室质量有轻度改善,无临床恶化。还对与 FD 相关的 SSc 的相关文献进行了综述。

相似文献

1
Restrictive cardiomyopathy in a patient with systemic sclerosis and Fabry disease: a case-based review.硬皮病合并法布里病患者的限制性心肌病:基于病例的综述。
Rheumatol Int. 2020 Mar;40(3):489-497. doi: 10.1007/s00296-019-04453-y. Epub 2019 Oct 10.
2
Anderson-Fabry disease: a multiorgan disease.安德森-法布里病:一种多系统疾病。
Curr Pharm Des. 2013;19(33):5974-96. doi: 10.2174/13816128113199990352.
3
GLA Gene Mutation in Hypertrophic Cardiomyopathy with a New Variant Description: Is it Fabry's Disease?GLA 基因突变致肥厚型心肌病伴新变异型描述:是否为法布里病?
Arq Bras Cardiol. 2019 Jul 10;113(1):77-84. doi: 10.5935/abc.20190112.
4
An expert consensus document on the management of cardiovascular manifestations of Fabry disease.《法布瑞病心血管表现管理的专家共识文件》
Eur J Heart Fail. 2020 Jul;22(7):1076-1096. doi: 10.1002/ejhf.1960. Epub 2020 Aug 14.
5
Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.伴有严重心脏表现的法布里病患者新型α-半乳糖苷酶 A 突变。
Gene. 2014 Feb 10;535(2):365-9. doi: 10.1016/j.gene.2013.09.058. Epub 2013 Oct 17.
6
Usefulness of lyso-globotriaosylsphingosine in dried blood spots in the differential diagnosis between multiple sclerosis and Anderson-Fabry's disease.溶酶体神经酰胺三己糖苷在多发性硬化症与安德森-法布里病鉴别诊断中应用于干血斑的价值。
Mult Scler Relat Disord. 2020 Feb;38:101466. doi: 10.1016/j.msard.2019.101466. Epub 2019 Oct 23.
7
Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.阿加糖酶α对36例初治法布里病患者进行酶替代治疗的疗效与安全性。
BMC Pharmacol Toxicol. 2017 Jun 7;18(1):43. doi: 10.1186/s40360-017-0152-7.
8
Fabry disease: A fundamental genetic modifier of cardiac function.法布里病:心脏功能的基本遗传修饰因子。
Curr Res Transl Med. 2017 Jan-Mar;65(1):10-14. doi: 10.1016/j.retram.2016.09.001. Epub 2016 Nov 2.
9
The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease.尿苷酰基鞘氨醇及其类似物总量在法布里病诊断中的临床应用。
Clin Chim Acta. 2020 Jan;500:120-127. doi: 10.1016/j.cca.2019.10.005. Epub 2019 Oct 22.
10
Fabry Disease and the Heart: A Comprehensive Review.《法布瑞病与心脏:全面综述》。
Int J Mol Sci. 2021 Apr 23;22(9):4434. doi: 10.3390/ijms22094434.

引用本文的文献

1
Deficiency Caused Restrictive Cardiomyopathy via Disrupting Proteostasis.缺乏症通过破坏蛋白质平衡导致限制性心肌病。
Int J Biol Sci. 2022 Feb 28;18(5):2018-2031. doi: 10.7150/ijbs.69024. eCollection 2022.
2
A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia.关于哥伦比亚溶酶体贮积症的研究、诊断及管理的观点
Heliyon. 2020 Mar 28;6(3):e03635. doi: 10.1016/j.heliyon.2020.e03635. eCollection 2020 Mar.

本文引用的文献

1
Prospects of using cardiovascular magnetic resonance in the identification of arrhythmogenic substrate in autoimmune rheumatic diseases.心血管磁共振在自身免疫性风湿病致心律失常基质识别中的应用前景。
Rheumatol Int. 2018 Sep;38(9):1615-1621. doi: 10.1007/s00296-018-4110-5. Epub 2018 Jul 24.
2
Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease.中国法布里病患者血浆球三糖基鞘氨醇水平的临床意义
Exp Ther Med. 2018 Apr;15(4):3733-3742. doi: 10.3892/etm.2018.5889. Epub 2018 Feb 26.
3
Fabry disease revisited: Management and treatment recommendations for adult patients.
重新审视法布里病:成年患者的管理和治疗建议。
Mol Genet Metab. 2018 Apr;123(4):416-427. doi: 10.1016/j.ymgme.2018.02.014. Epub 2018 Feb 28.
4
Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.血浆溶血型Gb3:一种在酶替代疗法期间监测法布里病患者的生物标志物。
Clin Exp Nephrol. 2018 Aug;22(4):843-849. doi: 10.1007/s10157-017-1525-3. Epub 2017 Dec 29.
5
Restrictive Cardiomyopathies: The Importance of Noninvasive Cardiac Imaging Modalities in Diagnosis and Treatment-A Systematic Review.限制性心肌病:非侵入性心脏成像模态在诊断和治疗中的重要性——一项系统评价
Radiol Res Pract. 2017;2017:2874902. doi: 10.1155/2017/2874902. Epub 2017 Nov 15.
6
Fabry disease and its cardiac involvement.法布里病及其心脏受累情况。
J Gen Fam Med. 2017 May 8;18(5):225-229. doi: 10.1002/jgf2.76. eCollection 2017 Oct.
7
Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice.法布瑞病患者的室性心律失常和心源性猝死:临床实践中风险因素的系统综述。
Europace. 2018 Sep 1;20(FI2):f153-f161. doi: 10.1093/europace/eux261.
8
Multimodality Imaging in Restrictive Cardiomyopathies: An EACVI expert consensus document In collaboration with the "Working Group on myocardial and pericardial diseases" of the European Society of Cardiology Endorsed by The Indian Academy of Echocardiography.限制型心肌病的多模态影像学:欧洲心血管影像协会专家共识文件 与欧洲心脏病学会“心肌和心包疾病工作组”合作 得到印度超声心动图学会的认可。
Eur Heart J Cardiovasc Imaging. 2017 Oct 1;18(10):1090-1121. doi: 10.1093/ehjci/jex034.
9
Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis.英国系统性硬化症研究小组的共识最佳实践路径:系统性硬化症中心脏病的管理
Rheumatology (Oxford). 2017 Jun 1;56(6):912-921. doi: 10.1093/rheumatology/kew488.
10
Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes.血浆溶酶体Gb3:法布里病杂合子诊断和治疗的有用生物标志物。
Mol Genet Metab. 2017 Jan-Feb;120(1-2):57-61. doi: 10.1016/j.ymgme.2016.10.006. Epub 2016 Oct 19.